Hydroxychloroquine in Previously Treated Patients With Metastatic Pancreatic Cancer
Status:
Completed
Trial end date:
2014-02-01
Target enrollment:
Participant gender:
Summary
Hydroxychloroquine is approved for the treatment of non-cancerous illnesses such as
rheumatoid arthritis and systemic lupus erythematous. Researchers in the laboratory have
tested tumors from patients with pancreatic cancer and have discovered that they have certain
pathways inside the cells that promote growth and survival of the tumor. Hydroxychloroquine
may inactivate these pathways and results in the death of pancreatic cancer cells.
Phase:
Phase 2
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborators:
Brigham and Women's Hospital Massachusetts General Hospital